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Isopentenol Utilization Pathway for the Production of
Linalool in Escherichia coli Using an Improved Bacterial
Linalool/Nerolidol Synthase
Clara A. Ferraz,[a] Nicole G. H. Leferink,[a, b] Iaroslav Kosov,[a] and Nigel S. Scrutton*[a, b]
Linalool is a monoterpenoid used as a fragrance ingredient, and
is a promising source for alternative fuels. Synthetic biology
offers attractive alternative production methods compared to
extraction from natural sources and chemical synthesis. Lina-
lool/nerolidol synthase (bLinS) from Streptomyces clavuligerus is
a bifunctional enzyme, producing linalool as well as the
sesquiterpenoid nerolidol when expressed in engineered
Escherichia coli harbouring a precursor terpenoid pathway such
as the mevalonate (MVA) pathway. Here we identified two
residues important for substrate selection by bLinS, L72 and
V214, where the introduction of bulkier residues results in
variants with reduced nerolidol formation. Terpenoid produc-
tion using canonical precursor pathways is usually limited by
numerous and highly regulated enzymatic steps. Here we
compared the canonical MVA pathway to the non-canonical
isopentenol utilization (IU) pathway to produce linalool using
the optimised bLinS variant. The IU pathway uses isoprenol and
prenol to produce linalool in only five steps. Adjusting
substrate, plasmid system, inducer concentration, and cell strain
directs the flux towards monoterpenoids. Our integrated
approach, combining enzyme engineering with flux control
using the artificial IU pathway, resulted in high purity
production of the commercially attractive monoterpenoid
linalool, and will guide future efforts towards efficient optimisa-
tion of terpenoid production in engineered microbes.
Introduction
Terpenoids (or isoprenoids) are an abundant and diverse class
of natural products with more than 80,000 compounds
described in the Dictionary of Natural Compounds.[1] Most
terpenoids are commonly found in plants where they exhibit a
multitude of biological roles, ranging from species-to-species
communication, to intracellular signalling, and defence against
predatory species.[2] Due to their structural diversity, terpenoids
also have a wide range of industrial applications and are used
as pharmaceuticals, herbicides, flavourings, fragrances and as
alternatives for fossil fuels.[3] Linalool is an odoriferous acyclic
terpenoid, predominantly occurring in nature as (R)-(  )-linalool
and contributes to the floral scent in over 200 plant species of
different families.[4] In 2019 the global linalool market valued
9,980 million USD, and is expected to grow 3.6% over the next
five years, reaching 12,300 million dollars in 2024.[5] Linalool is
widely used in cosmetic products like perfumes, lotions, soaps,
and shampoos, as well as in non-cosmetic household products
such as detergents, and cleaning agents. Furthermore, linalool
is vital to the manufacturing of Vitamin E.[6] More recently,
linalool and other terpenoids have attracted attention as
candidates for jet fuel replacements due their low freezing
point and high energy density.[7] Limitations, such as low levels
of terpenoids produced by plants and naturally occurring
microorganisms, stereo-chemical complexities and use of haz-
ardous solvents for their chemical synthesis, have directed
research efforts towards the development of engineered
microbes for the production of terpenoids.[8]
All terpenoids are naturally synthesized from the C5
building blocks isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMAPP). The combination of IPP and DMAPP can
generate diphosphate substrates of varying carbon lengths,
which can then be utilized by terpenoid synthases to produce
monoterpenoids (C10), sesquiterpenoids (C15), diterpenoids
(C20), or larger terpenoids. For example, geranyl diphosphate
(GPP), the universal substrate for monoterpenoids is synthesized
by head-to-tail coupling of one molecule each of DMAPP and
IPP. The addition of another IPP unit to GPP results in farnesyl
diphosphate (FPP), the precursor for all sesquiterpenoids.
Eukaryotes and archaea produce IPP and DMAPP through the
mevalonate (MVA) pathway, while most bacteria, some eukary-
otic parasites and plant chloroplasts use the 2-C-methyl-D-
erythritol 4-phosphate (MEP) pathway. The MVA and the MEP
pathways are composed of 18 enzymatic steps to produce IPP
or DMAPP from glucose,[9] and both pathways were previously
engineered in Escherichia coli and other prokaryotic and
eukaryotic organisms to produce terpenoids.
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Linalool has been successfully produced in engineered yeast
or E. coli as a host using a heterologous MVA pathway or the
endogenous MEP pathway with linalool synthases from plant or
bacterial sources.[10] However, plant linalool synthases, when
expressed in either yeast or E. coli, result in very low product
titres (<1 mgL  1).[10a–d] The use of a bacterial linalool/nerolidol
synthase (bLinS) from Streptomyces clavuligerus resulted in
much higher linalool titres (up to 500 mgL  1).[10e,f] But, because
bLinS also accepts FPP as substrate, which is naturally produced
by E. coli, the sesquiterpene trans-nerolidol is produced as by-
product (~30% of total product mixture).[10f] For commercial
production the generation of single, clean products is desirable,
as this would require less downstream processing.
One approach to reduce the formation of the nerolidol by-
product is to engineer bLinS so that it no longer accepts FPP as
substrate. Structural analysis of bLinS and the related enzyme
cineole synthase (bCinS) provides a rationale for the fact that
bLinS can accept both GPP and FPP as substrate, while bCinS
can only convert GPP. Crucially, the bCinS active site is rich in
bulky aromatic residues where bLinS contains smaller, non-
aromatic, residues resembling bacterial sesquiterpene syn-
thases. These residues offer attractive protein engineering
targets aiming at active site restriction for improved linalool
production (Figure 1,[10f] ).
Alternatively, the metabolic flux can be directed towards
monoterpenoids over larger terpenoids. The E. coli FPP synthase
(IspA) gene is not essential for viability, but FPP is a precursor to
essential compounds such as dolichols and respiratory
quinones,[11] and as such, IspA knock-out mutants show a
substantial reduction in growth rate.[11] Removal of FPP from
the substrate pool via an IspA knock-out in the E. coli terpenoid
production strain is therefore not a viable strategy to prevent
nerolidol formation by bLinS. However, using alternative non-
canonical isoprenoid precursor pathways the flux may be
directed away from FPP towards GPP.
Pathways orthogonal to the central metabolism can be
more effective for chemical production as they can bypass
highly regulated steps, avoid toxic intermediate accumulation
and reduce carbon loss related to precursor synthesis.[12]
Alternative non-canonical pathways that bypass the MVA path-
way were recently developed for this purpose.[13] One strategy
consists of using isoprenol (3-methyl-3-buten-1-ol) or prenol (3-
methyl-2-buten-1-ol) alcohols as feedstock to produce IPP and
DMAPP in a pathway composed of only two or three enzymes.
This pathway was named by different groups as isopentenol
utilization (IU) pathway,[14] alcohol-dependent hemiterpenoid
pathway,[15] isoprenoid alcohol pathway[13] or terpenoid mini-
path,[16] depending on the enzymes used. The IU pathway uses
Saccharomyces cerevisiae choline kinase promiscuous activity to
phosphorylate isoprenol and prenol, Arabidopsis thaliana iso-
pentenyl phosphate kinase for the second phosphorylation step
and E. coli isopentenyl-diphosphate delta-isomerase to inter-
convert IPP and DMAPP (Scheme 1). By supplying different
amounts of isoprenol and prenol, it is possible to direct the
biosynthesis towards the terpenoid of interest, as IPP and
DMAPP are consumed at different ratios depending on the
product of interest.[9]
Here we compared linalool production using the canonical
MVA pathway to the artificial IU pathway using an integrated
approach, combining protein engineering with flux control to
improve titres and product purity in E. coli. We identified two
important residues (L72 and V214) for GPP or FPP substrate
selection by bLinS. Their exchange for bulkier residues resulted
in bLinS variants with reduced nerolidol production. The IU
pathway uses isoprenol and prenol to produce linalool in only
five steps, and adjusting substrate concentration directs the flux
towards monoterpenoids. Plasmid, inducer and strain optimisa-
tions further increased linalool titres. The optimised IU pathway
produced 167 mgLorg




Previously we speculated that because bLinS contains smaller,
non-aromatic, residues at positions equivalent to bCinS Phe77
and Phe179 (Thr75 and Cys177 in bLinS), it resembles the
sesquiterpenoid synthases aristocholene synthase and selina-
diene synthase. This could explain why bLinS accepts GPP and
FPP as substrates whilst bCinS, with a smaller active site, only
converts GPP.[17] Structural analysis of bLinS and the related
bCinS (Figure 1), revealed several candidate amino acid residue
positions that could restrict access of FPP to the active site of
bCinS but not bLinS. The product profile of native bLinS
expressed in the engineered E. coli strain was determined
previously[17] by GC-MS analysis of the organic overlay (see
Figure S1 in the Supporting Information). The obtained linalool
titre was 360 mgLorg
  1, which constitutes approximately 65% of
all terpenoids collected in the organic layer, nerolidol was 29%
of the total and geraniol and derivatives, produced as a result
of endogenous E. coli activity together constituted about 6% of
the total terpenoid production.
Figure 1. Identification of bLinS target residues from structural analysis of
bLinS and bCinS. A) Cartoon representation of the bLinS structure in
complex with a fluorinated GPP analogue (PDB: 5NX5[17]). Residues identified
for mutagenesis are indicated, the fluorinated GPP analogue is shown in
yellow sticks and magnesium ions are represented as purple spheres. B)
Active site overlay of bLinS (green) and bCinS (PDB: 5NX7,[17] cyan). The
fluorinated substrate analogue is shown in yellow sticks and magnesium
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Residues Leu72, Thr75 and Cys177 were selected because
the equivalent positions in the related bCinS enzyme contain a
bulky phenylalanine residue (Figure 1B). In addition, residues
Leu72 and Thr75 align to a previously identified plasticity
region that is partly responsible for product outcome in plant
monoterpene cyclases/synthases.[18] Residues Ile176, Cys178,
Val214 and Phe295 were selected because of their position at
the bottom of the active site, and side-chain orientation
towards the substrate analogue in the crystal structure, which
potentially allows for a reduction in the size of the active site
cleft via the introduction of larger amino acids, thereby
preventing the binding of FPP via steric hindrance (Figure 1A).
All bLinS variants created were introduced in a pGPPS-bLinS
plasmid comprising Abies grandis GPPS and bLinS, in an E. coli
strain harbouring the pMVA plasmid[10a] for heterologous
expression of the MVA pathway. This allows the rapid
determination of full product profiles without the need for
expensive GPP and FPP substrates and laborious protein
purification steps.[19] Variant strains were grown in two-phase
shake-flask cultures using glucose as the carbon source and n-
nonane as the organic phase to trap the volatile terpenoids
produced. In the first round of mutagenesis a bulky phenyl-
alanine (Phe, F) residue was introduced at one or more
positions to replace Leu72, Thr75, and Cys177 to mimic the
smaller active site cavity of bCinS. Full product profiles of the
variants were obtained upon insertion of the variants in our
previously established MVA-dependent monoterpenoid produc-
tion platform[19] (see Figures S6, S11 and Table S6 in the
Supporting Information). Geraniol and farnesol are not pro-
duced by purified native bLinS in vitro,[17] but by endogenous E.
coli activity, and are thus ‘reporter’ products for the availability
of both GPP and FPP in the substrate pool. Interestingly most E.
coli strains harbouring these variants did not produce linalool
or nerolidol. Only the strain containing variant L72F produces a
very small amount of linalool (<3 mgLorg
  1) all other strains
only produce geraniol and derivatives at concentrations ranging
from 10–35 mgLorg
  1, which is the result of endogenous E. coli
activity.[18,20] Introduction of Phe at positions Ile176, Cys178 and
Val214, and a tryptophan (Trp, W) at position Phe295 had a
similar effect, and expression in the monoterpenoid production
platform resulted in strains that only produced geraniol and
derivatives, suggesting that neither FPP nor GPP are accepted
as substrates in these bLinS variants.
A second round of mutagenesis was conducted at the same
amino acid positions, introducing amino acids that are bulkier
than the original residues. A methionine residue (Met, M) was
introduced at positions Leu72, Thr75 and C178, a leucine (Leu,
L) residue was introduced at position Val214, and a tyrosine
(Tyr, Y) residue was introduced at position Phe295. All E. coli
strains harbouring these second round bLinS variants were
capable of producing linalool, albeit at a very low level for
variants T75M, C178M and F295Y (1–5 mgLorg
  1) (see Figure S7
and Table S6 in the Supporting Information). Two variants show
favourable product profiles; variant L72M has a linalool
Scheme 1. IU pathway and the proposed mechanism for the formation of linalool and trans-nerolidol in the engineered E. coli strain using the GPPS-bLinS
module. Isoprenol and prenol are phosphorylated by choline kinase (CK) producing isopentenyl phosphate (IP) and dimethylallyl phosphate (DMAP),
respectively. A second phosphorylation is catalysed by isopentenyl phosphate kinase (IPK), producing isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMAPP), which are isomerized by isopentenyl diphosphate delta-isomerase (IDI), shown in blue. The C5 isoprenoid precursors are converted to
the mono- and sesquiterpenoid substrates geranyl diphosphate (GPP) and farnesyl diphosphate (FPP) by a heterologous truncated GPP synthase (trGPPS) and
an endogenous FPP synthase (IspA) respectively. bLinS accepts both GPP and FPP which are converted to linalool and trans-nerolidol, respectively.
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production level similar to native bLinS (430 mgLorg
  1), but a
lower nerolidol production (8% of total terpenoids production).
Variant V214L, has a relatively low linalool titre compared to
native bLinS (50 mgLorg
  1), but the relative nerolidol production
is even lower (<2%).
To further investigate the role of amino acid composition at
positions 72 and 214 in substrate acceptance and product
outcome, additional single and double variants were con-
structed. First, either L72 or V214 were replaced with a variety
of amino acids, to investigate if the size and polarity of the
residues at these positions are important. Both L72 and V214
can be replaced with a limited number of hydrophobic residues
of medium size, resulting in active variants that still produce
linalool (see Figure 2 and Figures S8, S9 and Table S6 in the
Supporting Information). The best variants, L72M, V214I, and
V214L were combined in two double variants, both of which
display favourable properties over the native enzyme (Fig-
ure S12). Variant L72M produces the highest relative linalool
content (>90% of total terpenoids), with linalool titres that are
higher than observed for native bLinS (630 mgLorg
-1 vs
360 mgLorg
  1). L72M-V214I has a similar relative product profile
to native bLinS, but expression in our platform results in even
higher linalool titres (up to 1 gLorg
  1), and L72M-V214L has the
highest linalool/nerolidol ratio, a cumulative effect of both
single mutations (see Figure S12 in the Supporting Information).
Residues at positions 72 and 214 both need to be hydrophobic
for linalool production, and size cannot deviate extensively
from the original residue. This suggests the effect of these
residues on substrate acceptance is of a steric nature. This is
consistent with observed product profiles of variants where a
smaller residue is introduced (e.g. L72A, L72T) which produce
more nerolidol than linalool. See Table S6 in the Supporting
Information for a full breakdown of all product profiles obtained
in this study. Interestingly, a recently discovered new clade of
fungal linalool/nerolidol synthases contains members that are
capable of producing clean linalool product profiles, even in the
presence of FPP substrate.[21] Residues involved in substrate
specificity in these fungal enzymes map to a different part of
the active site, close to the negatively charged diphosphate
group of the substrate, whereas the residues identified in this
study interact only with the hydrocarbon moiety of the
substrate. However future structural work is needed to confirm
this.
The in vivo product profiles were confirmed by in vitro
biotransformations on GPP and FPP with selected purified bLinS
variants (Figure 3). Interestingly, even though in the in vivo
experiments more linalool is produced than nerolidol, it appears
that WT bLinS actually prefers FPP over GPP. This suggests that
using the heterologous MVA pathway the intracellular GPP
concentration is higher than FPP, despite the presence of the
endogenous IspA gene. Variants that contain either the L72M or
V214L mutation prefer GPP over FPP, confirming their role in
substrate selection in bLinS. These studies also confirmed that
endogenous E. coli activity is the source of any detected
geraniol and farnesol, and are not the result of mutations
introduced in the bLinS gene.
IU pathway
Non-canonical precursor pathways have the potential to
increase terpenoid titres by overcoming inherent regulation of
the MEP and MVA pathways by increasing orthogonality.
Alternative pathways which use isoprenol and prenol as
substrates were recently exploited for mono-, sesqui-, di- and
Figure 2. Product profiles and titres obtained for bLinS variants with single
mutations at position 72 (A) and 214 (B). Product profiles obtained when
expressed in engineered E. coli for terpenoids production. Full product
profiles, titres, and standard deviations are shown in Table S6 of the
Supporting Information. WT is wild-type bLinS.
Figure 3. In vitro biotransformations of selected bLinS variants with excess
GPP and FPP. The average value and SD of two replicates are shown. No
geraniol or farnesol was detected in any of the reaction mixtures, confirming
that the source of geraniol and farnesol in in vivo production experiments is
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tetraterpenoids production and showed to be a promising
strategy for high-titre terpenoid production in E. coli.[13–15] The
IU pathway was compared to the MVA pathway for linalool
production using the WT and the best performing bLinS
variants.
Isoprenol and prenol toxicity
Previous reports have demonstrated the toxicity of short
alcohols to microbial hosts, affecting not only cell growth but
also product titre.[22] Before implementing the IU pathway to
produce linalool, isoprenol and prenol toxicity in E. coli was
evaluated. Measurements of optical density at 600 nm (OD600)
were performed at increasing concentrations of exogenous
isoprenol and prenol in terrific broth (TB) medium (Figure 4).
Low concentrations of isoprenol or prenol do not affect
microbial growth, but the addition of 50 mM and 100 mM of
each alcohol individually inhibits cellular growth. A recent study
also found the half-maximal inhibitory concentration of iso-
prenol to be 53 mM.[23] When the two compounds were added
in combination, the growth rate was reduced at 37.5 mM each
and the addition of both alcohols at 100 mM each inhibits cell
growth almost completely.
Linalool production using the IU pathway
The genes encoding the IU pathway developed by Chatzivasi-
leiou et al.[14] were cloned in the pMVA plasmid, thereby
replacing the MVA genes, resulting in the plasmid p(Iso)prenol.
This plasmid was co-transformed into E. coli NEB-5α cells with
the plasmid pGPPS-bLinS. Since a previous study has shown
that a single-plasmid system could perform better than a two-
plasmid system,[10e] a single-plasmid, p(Iso)prenol-GPPS-bLinS
was constructed, cloning the genes encoding the IU pathway
into the pMVA-GPPS-bLinS plasmid as described.
The two- and single-plasmid systems were tested for
linalool production using a concentration of 25 mM isoprenol in
the culture medium (concentration optimized by Chatzivasi-
leiou et al.[14]). Strains were grown in two-phase shake-flask
cultures using glucose as the carbon source and n-nonane as
the organic phase to trap the volatile terpenoids produced.
After 72 h, terpenoids were recovered from the organic layer
and analysed by GC-MS. Total terpenoid titres obtained from
the IU pathway were substantially lower than the titres
obtained with the MVA pathway. Only 0.2 mgLorg
  1 linalool was
produced using the two-plasmid system and approximately
8 mgLorg
  1 linalool using the single-plasmid system under the
same conditions (Figure 5A). Interestingly, the linalool/nerolidol
ratio obtained from the IU pathway was very different from the
one obtained using the MVA pathway, although the same
terpenoid synthase was used. Nerolidol was produced at higher
amounts by both systems, achieving 12 mgLorg
  1 in the two-
plasmid system, and 33 mgLorg
  1 in the single-plasmid system
(Figure 5A), suggesting a higher availability of FPP over GPP
compared to the MVA pathway. This correlates to the in vitro
results which shows that at an excess of GPP and FPP, WT bLinS
prefers the sesquiterpenoid precursor FPP.
Next, isoprenol was supplied at lower and higher concen-
trations to evaluate the impact on product titres. Although
linalool levels did not increase at any condition with the two-
plasmid system, decreasing the isoprenol amount to 12.5 mM
doubled the linalool titre to 16 mgLorg
  1 in the single-plasmid
system (Figure 5A). In all conditions tested, nerolidol titres were
at least doubled compared to linalool, reaching almost
50 mgLorg
  1 for the single-plasmid system supplied with
12.5 mM isoprenol. Total terpenoid titres were reduced at
higher substrate concentrations, which is most likely due to
increased substrate toxicity.
The nerolidol precursor, FPP, is obtained via the condensa-
tion of two units of IPP, the product of isoprenol phosphor-
ylation, and one unit of DMAPP, the product of prenol
phosphorylation (Scheme 1). The low linalool/nerolidol ratio
when isoprenol is supplied is possibly a reflection of a higher
Figure 4. Isoprenol and prenol toxicity in E. coli in TB medium under
different concentrations. Overnight E. coli NEB-5α cells were sub-cultured
and grown until OD600 =0.3–0.4. Isoprenol and prenol were added at
different concentrations and toxicity was determined through culture
growth in a 200 μL 96-well plate at 30 °C by measuring the OD600 for 24 h.





5ChemBioChem 2021, 22, 1–11 www.chembiochem.org © 2021 The Authors. ChemBioChem published by Wiley-VCH GmbH
These are not the final page numbers! ��
Wiley VCH Dienstag, 25.05.2021
2199 / 204329 [S. 5/11] 1
IPP availability over DMAPP, favouring the formation of
sesquiterpenoids over monoterpenoids. Next, isoprenol was
replaced with prenol as substrate to increase the amount of
DMAPP, and as such increase linalool levels over nerolidol
(Figure 5B). Indeed, an increase in the linalool/nerolidol ratio
was observed for all conditions, reaching a 1 :1 proportion for
most conditions using p(Iso)prenol-GPPS-bLinS. Approximately
25 mgLorg
  1 linalool was produced using the single-plasmid
system and 25 mM prenol. Linalool and nerolidol levels
remained low for the two-plasmid system. As for isoprenol, the
addition of prenol at higher concentrations (37.5 and 50 mM)
resulted in reduced product level (Figure 5B).
To further optimize secondary substrate supply, isoprenol
and prenol were added combined at equal concentration as a
tentative to mimic of the required IPP and DMAPP ratio to form
GPP (Figure 5C). The combination of substrates had little
influence on the product titres in the two-plasmid system, but
it further increased both linalool and nerolidol levels in the
single-plasmid system. In this case, linalool and nerolidol titres
reached 55 mgLorg
  1 and 75 mgLorg
  1 respectively, using a
combination of 12.5 mM isoprenol and 12.5 mM prenol. A
higher concentration of these substrates combined significantly
reduced monoterpenoid and sesquiterpenoid titres. These
initial experiments validated the superior performance of the
single-plasmid system over the two-plasmid system and the
best substrate concentration of 12.5 mM isoprenol and prenol.
These conditions were used for further optimization of linalool
production.
The influence of other parameters such as inducer concen-
tration and E. coli strain was next evaluated for linalool
production using the IU pathway. Inducer level is known to
have a direct impact on the metabolic burden imposed on the
cell, affecting growth rates, product levels, protein expression
and plasmid stability.[24] To determine the best inducer level,
the isopropyl β-D-1-thiogalactopyranoside (IPTG) concentration
was varied from 0 to 100 μM, and linalool and nerolidol titres
were determined. Within the IPTG concentration range tested,
50 μM gave the best results (Figure 6A).
Linalool production was evaluated using three different E.
coli strains (NEB-5α, NEB-10β, and BL21) (Figure 6B). Similar to
the results observed for the synthesis of larger terpenoids,[25]
linalool production had a significant strain dependence. NEB-
10β cells increased linalool production to almost 60 mgLorg
  1
and production of nerolidol to almost 90 mgLorg
  1 when
Figure 5. Linalool and nerolidol titres obtained with the IU pathway using a two-plasmid system (p(Iso)prenol+pGPPS-bLinS) or a single-plasmid system
(p(Iso)prenol-GPPS-bLinS) with different concentrations of isoprenol (A), prenol (B), and isoprenol and prenol together (C). E. coli NEB-5α cells were grown in
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12.5 mM isoprenol and prenol was used as feedstock. Using
BL21 cells, the monoterpenoid production decreased to
12 mgLorg
  1. This strain also showed lower linalool/nerolidol
ratio, producing 29 mgLorg
  1 nerolidol. Although BL21 cells are
widely used for protein expression, high gene expression can
lead to the formation of protein aggregates or surplus synthesis
of proteins in part, resulting in an adverse metabolic pathway
balance.[26]
Having identified residues that influence linalool and
nerolidol production, the best performing bLinS variants, L72M
and L72M-V214I were tested in the IU pathway using the p(Iso)
prenol-GPPS-bLinS plasmid. Linalool titres increased with both
variants, reaching almost 80 mgLorg
  1 using the L72M-V214I
bLinS and NEB-5α cells, and 167 mgLorg
  1 using L72M-V214I
bLinS and NEB-10β cells, the highest linalool titre obtained
using the IU pathway to date (Figure 7).
Crucially, for the first time nerolidol titres remained lower
than linalool levels using the IU pathway, representing approx-
imately 27 and 17% of total terpenoids produced using the
L72M and L72M-V214I variants, respectively. Similar to what
was observed with the MVA pathway, both bLinS variants
increased linalool titres compared to wild type bLinS, but the
double variant also increased the linalool/nerolidol ratio
compared to the WT bLinS. Interestingly, these results are
aligned to what was observed in the in vitro assay. Although
both the MVA pathway and IU pathway are responsible for
producing the IPP and DMAPP pool, which is used by prenyl
transferases to elongate terpenoid chains, the higher relative
amount of nerolidol from the IU pathway suggests a greater
availability of FPP over GPP compared to the MVA pathway,
even under optimised conditions.
Although linalool levels produced through the IU pathway
were lower than the titres obtained with the MVA pathway
(Figure 8), this should not eclipse its potential. The MVA
pathway was first engineered in E. coli almost two decades ago,
and the first terpenoid titres obtained were also on the level of
a few dozens to a hundred mg/L.[8b] Since then, numerous
studies identified and optimized fermentation conditions, feed-
back-resistant enzymes, accumulation of toxic intermediates,
Figure 6. Linalool and nerolidol titres obtained with the IU pathway using the plasmid p(Iso)prenol-GPPS-bLinS, 12.5 mM isoprenol and prenol as substrates,
with different IPTG concentrations (A), and different cell strains (B). E. coli cells were grown in 3 mL TB media with 20% n-nonane overlay for 72 h. Error bars
represent the standard deviation of three biological replicates.
Figure 7. Linalool and nerolidol titres obtained with the IU pathway using
the plasmid p(iso)prenol-GPPS-bLinS, 12.5 mM isoprenol and prenol as
substrates, NEB-5α and NEB-10β cells and different bLinS variants. E. coli cells
were grown in 3 mL TB media with 20% n-nonane overlay for 72 h. Error
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and other process and metabolic bottlenecks, allowing the
increase of terpenoid titres. We report the use of IU pathway to
produce terpenoids in E. coli for the second time and the
monoterpenoid titres obtained are already superior to the ones
obtained previously.[14] The isoprenol and prenol utilizing path-
ways were only recently discovered, and little is known about
how the enzymatic steps are regulated. A similar pathway
developed by Clomburg et al. produced up to 2 gL  1 geranoids,
showing that with further optimization it is possible to reach
titres comparable to the ones achieved using the MVA
pathway.[13]
The IU pathway strategy benefits from a reduced number of
genes, which can lead to an accelerated and easier optimization
process. Our changes in plasmid system, substrate and inducer
concentration, and host cell strain increased linalool titre 280-
fold compared to initial conditions. Using an improved bLinS
variant further tripled linalool titres and allowed formation of
fewer by-products resulting in a more pure product. A major
advantage of the IU pathway over the MVA pathway is the
ability to direct flux to GPP or FPP by balancing the prenol and
isoprenol feedstock concentrations, resulting in a more versatile
terpenoid production platform. The manipulation of other
parameters using the metabolic engineering toolbox may
further improve carbon flux towards the terpenoid of interest.
Conclusion
Linalool is a monoterpenoid with applications ranging from
cosmetic products to biofuels, and over half of total linalool
consumed is produced through traditional chemical
processes.[27] In this study, we created bLinS variants which
resulted in increased linalool and reduced nerolidol levels when
expressed in engineered E. coli for the production of terpenoids.
Mutations L72M and V214I/L were shown to act as gatekeepers
for FPP acceptance by re-shaping the active site. WT and bLinS
variants were co-expressed with the canonical MVA pathway
and L72M-V214I mutation in bLinS increased linalool titres
almost 3-fold, producing 1054 mgLorg
  1 linalool. Nerolidol titres
corresponded to 26% total terpenoid recovered and reached
379 mgLorg
  1.
We compared the MVA pathway to the non-canonical IU
pathway which uses isoprenol and prenol as secondary
substrates to form the terpenoid building blocks IPP and
DMAPP, through a reduced number of enzymatic steps. We
balanced isoprenol and prenol concentrations to modulate
linalool and nerolidol titres, and optimised plasmid system,
inducer concentration and cell type. Insertion of the engineered
bLinS variants into the improved IU pathway increased linalool
titres 800-fold to 167 mgLorg
  1 with a reduction in nerolidol
levels to 17% of total terpenoid products.
Even though the highly optimised canonical MVA pathway
results in higher linalool titres, compared to the IU pathway, the
latter offers a more flexible terpenoid production platform with
potential for further improvement. Decoupling product syn-
thesis from central metabolism can increase the metabolic flux
to the desired product. The intracellular GPP/FPP ratio can be
balanced to match the product of interest using different
prenol/isoprenol concentrations, without the need for addi-
tional genes or enzyme optimisation. The fewer number of
genes in the IU pathway minimises the accumulation of
potentially toxic intermediates, and simplifies future optimisa-
tion steps.
In conclusion, our results show a promising new and simpler
pathway to produce linalool, and it adds to other similar
initiatives to produce other terpenoids from isoprenol and
prenol. Our proof of principle study resulted in 800-fold
improved linalool titres using minimal engineering. There is still
a lack of understating of how this pathway is regulated and the
identity of bottlenecks within the pathway. Further pathway
tuning will lead to elucidation of how the metabolic flux is
directed and this will form the basis of further pathway
optimization.
Experimental Section
Chemicals: GPP and FPP substrates were synthesized from geraniol
and farnesol respectively as described previously.[28]
Bacterial strains and media: All E. coli strains were routinely grown
in Lysogeny Broth (LB) or on LB agar plates including antibiotic
supplements as appropriate (carbenicillin, 100 μgmL  1; kanamycin,
50 μgmL  1). Mutagenesis and plasmid propagation was performed
using E. coli Stellar cells (Clontech). Terpenoids production was
Figure 8. Comparison of optimised linalool and nerolidol product titres (A)
and product ratio (B) obtained with the MVA pathway (NEB-5α cells) and the
IU pathway (NEB-10β cells, 12.5 mM each isoprenol and prenol as substrates)
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performed in phosphate buffered TB using E. coli DH5α, DH10β and
BL21 (NEB 5α, NEB 10β and BL21(DE3), New England Biolabs).
Isoprenol and prenol toxicity: OD600 measurements were per-
formed to evaluate isoprenol and prenol toxicity on E. coli NEB-5α
cells at different concentrations. Cultures from frozen glycerol
stocks were incubated in 20 mL TB medium and grown overnight
at 37 °C and 180 rpm. Overnight cultures were diluted with 25 mL
TB medium in a ratio of 1 :100, and incubated at 37 °C and 180 rpm
until OD600 reached 0.4. 160 μL of the culture was transferred to a
96-well plate previously filled with 40 μL solution of TB medium
and isoprenol and/or prenol at the desired concentration. The
microplate was transferred to a BMG Labtech ClarioStar plate reader
and incubated at 30 °C and 300 rpm. OD600 measurements were
made at least in triplicate for each sample over 24 h. The range of
concentration evaluated was from 3 to 100 mM of isoprenol, 3 to
100 mM of prenol, and 3 to 100 mM of isoprenol and prenol in a
1 :1 ratio.
Plasmid construction and site-directed mutagenesis: The pMVA-
GPPS-bLinS plasmid was constructed by replacing the limonene
synthase (LimS) in plasmid pJBEI6410[29] with linalool synthase from
Streptomyces clavuligerus (bLinS).[17] The bLinS gene was amplified
from plasmid pGPPSmTC/S38[17] using primer pair LinS+6410-Fw/
Rv. The pJBEI6410 plasmid, except LimS, was amplified using primer
pair pJ6410_Syn_open3-Fw and pJ6410_Syn_open5_Rv (Table S2).
The fragments were ligated using the In-Fusion® HD Cloning
method (TaKaRa) following the manufacturer’s instructions.
Gene sequences encoding the Isopentenol utilization (IU) pathway
developed by Chatzivasileiou et al.[14] were designed, codon-
optimized for E. coli, and purchased from GeneArt, Thermo Fisher
Scientific in a pET21b plasmid. ScCK-AtIPK-EcIDI genes (Table S1)
were amplified from the pET21b plasmid and EcoRI restriction site
was added by PCR using DNA polymerase CloneAmp™ HiFi PCR
Premix (Clontech) and primers pET21b-EcoRI_Fw, and pET21b_Rv
(Table S2), according to manufacturer’s recommendation. PCR
product was digested with EcoRI and XhoI, and run on a 1%
agarose gel. The band corresponding to the ScCK-AtIPK-EcIDI
fragment was gel extracted and purified. pMVA plasmid (Table S4)
was digested with EcoRI and XhoI, and the band corresponding to
plasmid vector was gel extracted and purified. Vector and the
fragment were ligated to obtain the p(Iso)prenol plasmid using
New England Biolabs Quick Ligation™ kit. The product of ligation
was transformed into competent E. coli NEB 5α cells. p(Iso)prenol-
GPPS-bLinS plasmid was obtained using In-Fusion® HD Cloning
method (TaKaRa). Plasmid vector was linearized by PCR from the
pMVA-GPPS-bLinS plasmid (Table S4) with the primers pMVA-
prenol-bLinS_V_Fw and pMVA-prenol-bLinS_V_Rv (Table S2), and
the ScCK-AtIPK-EcIDI fragment was linearized by PCR from the
p(Iso)prenol plasmid using the primers pMVA-prenol-bLinS_F_Fw
and pMVA-prenol-bLinS_F_Rv (Table S2) according to manufac-
turer’s recommendation. Mutations were introduced in bLinS using
the QuikChange site-directed mutagenesis method (Stratagene)
using plasmid pGPPSmTC/S38, pET-bLinS, or p(Iso)prenol-GPPS-
bLinS encoding native bLinS[17] as template. The oligonucleotides
used are shown in Table S3. All plasmids were confirmed by
standard Sanger sequencing.
Terpenoid production in E. coli: For terpenoid production, p(Iso)
prenol-GPPS-bLinS or a pGPPSmTC/S plasmid (Table S4) harbouring
native or a variant bLinS gene was co-transformed with p(Iso)
prenol or pMVA into E. coli DH5α and grown as described
previously.[19] Briefly, expression strains were inoculated at 37 °C in
3 mL TB supplemented with 0.4% glucose and the appropriate
antibiotics in glass screw capped vials. After 7 h, isoprenol and/or
prenol were added accordingly together with inducers (50 μM IPTG
and 25 nM anhydro-tetracycline, unless otherwise indicated) and
20% n-nonane organic layer to capture the volatile terpenoid
products. After 72 h at 30 °C, the n-nonane overlay was collected,
dried over anhydrous MgSO4 and mixed at a 1 :1 ratio with ethyl
acetate containing 0.01% (v/v) sec-butylbenzene or 0.1% (v/v)
limonene as internal standards for GC-MS analysis.
Expression and purification of bLinS variants: E. coli ArcticExpress
(DE3) cells were freshly transformed with a pET-bLinS plasmid
(Table S4), and induced with 0.1 mM IPTG for 16 h at 16 °C. The
recombinant proteins were purified as described previously.[17]
Briefly, the cells were harvested and resuspended in buffer A
(25 mM Tris pH 8.0, 150 mM NaCl, 1 mM DTT, 4 mM MgCl2 and 5%
(v/v) glycerol). The cells were lysed by sonication and the debris
was removed by centrifugation. The supernatant was loaded onto a
His-Trap column (GE Healthcare) pre-equilibrated with buffer A
containing 25 mM imidazole. The column was washed with buffer
A containing 25 mM imidazole, and the proteins were eluted by
increasing the imidazole concentration to 100 mM and 500 mM.
Fractions containing the purified proteins were pooled, concen-
trated and desalted using a PD10 column (BioRad) prior to storage
at   80 °C.
In vitro biotransformations: All biotransformation reactions with
purified enzyme were prepared in duplicate in buffer A in glass
vials. For product profile determination, the reaction mixtures
(0.25 mL) contained 0.4 mM GPP, or FPP and 1 μM purified enzyme,
and a 100% (v/v) n-nonane layer was added to capture the volatile
monoterpenoid products. The vials were incubated at 30 °C with
gentle shaking for 5 min. The reaction was stopped by placing the
vials on ice, followed by immediate vortexing for 30s. The n-nonane
overlay was collected, dried over anhydrous MgSO4 and mixed at a
1 :1 ratio with ethyl acetate containing 0.01% (v/v) sec-butylben-
zene as internal standard. The samples were analysed by GC-MS.
GC-MS analysis: The samples were injected onto an Agilent
Technologies 7890B GC equipped with an Agilent Technologies
5977A MSD. The products were separated on a DB-WAX column
(30 m×0.32 mm i.d., 0.25 μM film thickness, Agilent Technologies).
The injector temperature was set at 240 °C with a split ratio of 20 :1
(1 μL injection). The carrier gas was helium with a flow rate of
1 mLmin  1 and a pressure of 5.1 psi. The following oven program
was used: 50 °C (1 min hold), ramp to 68 °C at 5 °Cmin  1 (2 min
hold), and ramp to 230 °C at 25 °Cmin  1 (2 min hold). The ion
source temperature of the mass spectrometer (MS) was set to
230 °C and spectra were recorded from m/z 50 to m/z 250.
Compound identification was carried out using authentic standards
and comparison to reference spectra in the NIST library of MS
spectra and fragmentation patterns as described previously.[19]
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Linalool is a monoterpenoid used as
fragrance ingredient, and a
promising source for alternative
fuels. Here we explore the artificial
isoprenol utilization pathway to
produce linalool in Escherichia coli
using the linalool/nerolidol synthase
from Streptomyces clavuligerus. The
generation of improved bLinS
variants together with substrate and
strain optimization increased linalool
production and decreased nerolidol
by-product levels.
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